A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Additional signs that might be mistaken for poor circulation include pins and needles sensations, coldness at the extremities ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Other symptoms may mimic signs of poor circulation like pins and needles, cold extremities, pale or blue skin, muscle ...
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...
Eight specific habits — diet, sleep, physical activity, smoking, body mass index, blood glucose, lipids and blood pressure — ...
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:45 PM EDT. About LeMaitre ...